Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04170985 · ClinicalTrials.gov registry record
NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 160
- Enrollment target
NCT04170985 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 160 participants.
The verdict
NCT04170985 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enrollment.
Interventions
- OTHER clinical Whole Genome Sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2024-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04170985
The ClinicalTrials.gov registry entry for NCT04170985 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Illumina, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clinical Whole Genome Sequencing is the first listed.
NCT04170985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04170985 about?
NCT04170985 is a clinical study titled "NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology". Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enroll...
What is the current status of trial NCT04170985?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2019-11-18. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04170985?
The interventions under investigation include: clinical Whole Genome Sequencing (OTHER).
Who is sponsoring clinical trial NCT04170985?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.